<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<addis-data xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://drugis.org/files/addis-6.xsd">
    <units>
        <unit name="gram" symbol="g"/>
        <unit name="liter" symbol="l"/>
    </units>
    <indications>
        <indication code="38341003" name="Hypertensive disorder"/>
    </indications>
    <drugs>
        <drug name="Azilsartan" atcCode="C09CA09"/>
        <drug name="Olmesartan" atcCode="C09CA08"/>
        <drug name="Placebo" atcCode="Placebo"/>
        <drug name="Valsartan" atcCode="C09CA03"/>
    </drugs>
    <treatmentCategorizations/>
    <endpoints>
        <endpoint name="DBP 12-hour mean" description="Change from baseline in the 12-hour mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP 24-hour mean" description="Change from baseline in the 24-hour mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP daytime mean" description="Change from baseline in daytime (6am - 10pm) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP mean trough (clinic, sitting)" description="Change from baseline in mean trough clinic sitting diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP nighttime mean" description="Change from baseline in the nighttime (12am - 6am) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP response (clinic)" description="Participants who achieve a clinic diastolic blood pressure response, defined as &lt; 90 mmHg and/or reduction from baseline at least 10 mmHg" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="DBP trough mean" description="Change from baseline in the trough (22-24hr) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP 12-hour mean" description="Change from baseline in the 12-hour mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP 24-hour mean" description="Change from baseline in the 24-hour mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP and DBP response (clinic)" description="Participants who achieve both clinic SBP and clinic DBP response" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="SBP daytime mean" description="Change from baseline in daytime (6am - 10pm) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP mean trough (clinic, sitting)" description="Change from baseline in mean trough clinic sitting systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP nighttime mean" description="Change from baseline in nighttime (12am - 6am) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP response (clinic)" description="Participants who achieve a clinic systolic blood pressure response, defined as &lt; 140 mmHg and/or reduction frome baseline at least 20 mmHg" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="SBP trough mean" description="Change from baseline in the trough (22-24hr) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
    </endpoints>
    <adverseEvents>
        <adverseEvent name="Abdominal adhesions" description="Abdominal adhesions (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Atrial fibrillation" description="Atrial fibrillation (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Blood pressure increased" description="Blood pressure increased (Investigations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Breast cancer" description="Breast cancer (Neoplasms benign, malignant and unspecified (incl cysts and polyps))" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cellulitis" description="Cellulitis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Chest pain" description="Chest pain (General disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cholecystitis" description="Cholecystitis (Hepatobiliary disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cholecystitis chronic" description="Cholecystitis chronic (Hepatobiliary disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cholelithiasis" description="Cholelithiasis (Hepatobiliary disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Coronary artery disease" description="Coronary artery disease (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Deep vein thrombosis" description="Deep vein thrombosis (Vascular disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Diverticulitis" description="Diverticulitis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Dysfunctional uterine bleeding" description="Dysfunctional uterine bleeding (Reproductive system and breast disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Dyslipidemia" description="Dyslipidemia (Metabolism and nutrition disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Epilepsy" description="Epilepsy (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Eye irritation" description="Eye irritation (Eye disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Fall" description="Fall (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Gastrointestinal haemorrhage" description="Gastrointestinal haemorrhage (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Headache" description="Headache (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Infected bites" description="Infected bites (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Inguinal hernia" description="Inguinal hernia (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Intentional overdose" description="Intentional overdose (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Ischaemia" description="Ischaemia (Vascular disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Ischaemic stroke" description="Ischaemic stroke (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Lower respiratory tract infection" description="Lower respiratory tract infection (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Myelodysplastic syndrome" description="Myelodysplastic syndrome (Neoplasms benign, malignant and unspecified (incl cysts and polyps))" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Myocardial infarction" description="Myocardial infarction (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Non-SAE" description="Non-serious adverse events (total)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Partial seizures" description="Partial seizures (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Pneumonia" description="Pneumonia (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="SAE" description="Serious adverse events" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Shock" description="Shock (Vascular disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Status asthmaticus" description="Status asthmaticus (Respiratory, thoracic and mediastinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Subdural haematoma" description="Subdural haematoma (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Transient ischaemic attack" description="Transient ischaemic attack (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
    </adverseEvents>
    <populationCharacteristics>
        <populationCharacteristic name="Age (cut-off 45, 65)" description="Age in years">
            <categorical>
                <category>&lt; 45</category>
                <category>45-64</category>
                <category>&gt; 64</category>
            </categorical>
        </populationCharacteristic>
        <populationCharacteristic name="Gender" description="Gender (male, female)">
            <categorical>
                <category>Female</category>
                <category>Male</category>
            </categorical>
        </populationCharacteristic>
    </populationCharacteristics>
    <studies>
        <study name="NCT00696241">
            <indication name="Hypertensive disorder">
                <notes>
                    <note source="CLINICALTRIALS">Hypertension</note>
                </notes>
            </indication>
            <characteristics>
                <title>
                    <value>Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension</value>
                    <notes>
                        <note source="CLINICALTRIALS">Brief title: Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Official title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension</note>
                    </notes>
                </title>
                <allocation>
                    <value>RANDOMIZED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </allocation>
                <blinding>
                    <value>DOUBLE_BLIND</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </blinding>
                <centers>
                    <value>85</value>
                    <notes>
                        <note source="CLINICALTRIALS">Birmingham, Alabama, United States
Huntsville, Alabama, United States
Mesa, Arizona, United States
Phoenix, Arizona, United States
Tempe, Arizona, United States
Little Rock, Arkansas, United States
Tempe, Arkansas, United States
Beverly Hills, California, United States
Carmichael, California, United States
Fountain Valley, California, United States
Long Beach, California, United States
Los Gatos, California, United States
Orangevale, California, United States
Sacramento, California, United States
Santa Ana, California, United States
Spring Valley, California, United States
Tustin, California, United States
Westlake Village, California, United States
Colorado Springs, Colorado, United States
Farmington, Connecticut, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Jupiter, Florida, United States
Melbourne, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Ocala, Florida, United States
Pembroke Pines, Florida, United States
Sarasota, Florida, United States
St. Petersburg, Florida, United States
Augusta, Georgia, United States
Lawrenceville, Georgia, United States
Chicago, Illinois, United States
Melrose Park, Illinois, United States
Naperville, Illinois, United States
Round Lake Beach, Illinois, United States
Valparaiso, Indiana, United States
Wichita, Kansas, United States
Erlanger, Kentucky, United States
Lexington, Kentucky, United States
Auburn, Maine, United States
West Yarmouth, Massachusetts, United States
Benzonia, Michigan, United States
Chelsea, Michigan, United States
Omaha, Nebraska, United States
Trenton, New Jersey, United States
Wildwood Crest, New Jersey, United States
Albuquerque, New Mexico, United States
Brooklyn, New York, United States
Orangevale, New York, United States
Rochester, New York, United States
Burlington, North Carolina, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Statesville, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
Kettering, Ohio, United States
Lyndhurst, Ohio, United States
Marion, Ohio, United States
Norman, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Altoona, Pennsylvania, United States
Reading, Pennsylvania, United States
Mt. Pleasant, South Carolina, United States
Simpsonville, South Carolina, United States
Taylors, South Carolina, United States
Nashville, Tennessee, United States
New Tazewell, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Lake Jackson, Texas, United States
North Richland Hills, Texas, United States
San Antonio, Texas, United States
Draper, Utah, United States
Burke, Virginia, United States
Norfolk, Virginia, United States
Tacoma, Washington, United States
Madison, Wisconsin, United States
Provincia de Buenos Aires, Argentina
Provincia de Cordoba, Argentina
Aguascalientes,, Mexico
Mexico DF, Mexico
San Luis Potosi, Mexico
</note>
                    </notes>
                </centers>
                <objective>
                    <value>The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil,once daily (QD), compared to placebo and olmesartan in participants with essentialhypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil,once daily (QD), compared to placebo and olmesartan in participants with essentialhypertension.</note>
                    </notes>
                </objective>
                <study_start>
                    <value>2007-06-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">June 2007</note>
                    </notes>
                </study_start>
                <study_end>
                    <value>2008-10-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">October 2008</note>
                    </notes>
                </study_end>
                <status>
                    <value>COMPLETED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Completed</note>
                    </notes>
                </status>
                <inclusion>
                    <value>1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria

1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.

Exclusion Criteria

1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</note>
                    </notes>
                </inclusion>
                <exclusion>
                    <value>1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria

1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.

Exclusion Criteria

1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</note>
                    </notes>
                </exclusion>
                <references>
                    <pubMedId>21282560</pubMedId>
                    <pubMedId>21272195</pubMedId>
                </references>
                <source>
                    <value>CLINICALTRIALS</value>
                    <notes>
                        <note source="CLINICALTRIALS">http://clinicaltrials.gov/show/NCT00696241</note>
                    </notes>
                </source>
                <creation_date>
                    <value>2012-09-24</value>
                    <notes>
                        <note source="CLINICALTRIALS">Information obtained from ClinicalTrials.gov on September 20, 2012</note>
                    </notes>
                </creation_date>
            </characteristics>
            <studyOutcomeMeasures>
                <studyOutcomeMeasure id="endpoint-SBP 24-hour mean" primary="true">
                    <endpoint name="SBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="SBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 24-hour mean" primary="false">
                    <endpoint name="DBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="DBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
Description: The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP daytime mean" primary="false">
                    <endpoint name="SBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP daytime mean" primary="false">
                    <endpoint name="DBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP nighttime mean" primary="false">
                    <endpoint name="SBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP nighttime mean" primary="false">
                    <endpoint name="DBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 12-hour mean" primary="false">
                    <endpoint name="SBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 12-hour mean" primary="false">
                    <endpoint name="DBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP trough mean" primary="false">
                    <endpoint name="SBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP trough mean" primary="false">
                    <endpoint name="DBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP response (clinic)" primary="false">
                    <endpoint name="SBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline  20 mm Hg
Description: Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP response (clinic)" primary="false">
                    <endpoint name="DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline  10 mm Hg
Description: Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)" primary="false">
                    <endpoint name="SBP and DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
Description: Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-SAE" primary="false">
                    <adverseEvent name="SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, serious adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation" primary="false">
                    <adverseEvent name="Atrial fibrillation"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Atrial fibrillation (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Coronary artery disease" primary="false">
                    <adverseEvent name="Coronary artery disease"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Coronary artery disease (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Myocardial infarction" primary="false">
                    <adverseEvent name="Myocardial infarction"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Myocardial infarction (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage" primary="false">
                    <adverseEvent name="Gastrointestinal haemorrhage"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gastrointestinal haemorrhage (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Inguinal hernia" primary="false">
                    <adverseEvent name="Inguinal hernia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Inguinal hernia (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Chest pain" primary="false">
                    <adverseEvent name="Chest pain"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Chest pain (General disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic" primary="false">
                    <adverseEvent name="Cholecystitis chronic"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cholecystitis chronic (Hepatobiliary disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cellulitis" primary="false">
                    <adverseEvent name="Cellulitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cellulitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection" primary="false">
                    <adverseEvent name="Lower respiratory tract infection"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Lower respiratory tract infection (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Pneumonia" primary="false">
                    <adverseEvent name="Pneumonia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Pneumonia (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome" primary="false">
                    <adverseEvent name="Myelodysplastic syndrome"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Myelodysplastic syndrome (Neoplasms benign, malignant and unspecified (incl cysts and polyps))</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Epilepsy" primary="false">
                    <adverseEvent name="Epilepsy"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Epilepsy (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke" primary="false">
                    <adverseEvent name="Ischaemic stroke"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ischaemic stroke (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack" primary="false">
                    <adverseEvent name="Transient ischaemic attack"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Transient ischaemic attack (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Status asthmaticus" primary="false">
                    <adverseEvent name="Status asthmaticus"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Status asthmaticus (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Ischaemia" primary="false">
                    <adverseEvent name="Ischaemia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ischaemia (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Shock" primary="false">
                    <adverseEvent name="Shock"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Shock (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Non-SAE" primary="false">
                    <adverseEvent name="Non-SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, other adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Dyslipidemia" primary="false">
                    <adverseEvent name="Dyslipidemia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Dyslipidemia (Metabolism and nutrition disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Headache" primary="false">
                    <adverseEvent name="Headache"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Headache (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)" primary="false">
                    <populationCharacteristic name="Age (cut-off 45, 65)"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Gender" primary="false">
                    <populationCharacteristic name="Gender"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gender
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
            </studyOutcomeMeasures>
            <arms>
                <arm name="Azilsartan Medoxomil 20 mg QD" size="283">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 20 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 40 mg QD" size="283">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 40 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 80 mg QD" size="285">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 80 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Olmesartan 40 mg QD" size="282">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Olmesartan 40 mg QD
Arm Type: Active Comparator

Intervention Name: Olmesartan
Intervention Type: Drug
Intervention Description: Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Placebo QD" size="142">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Placebo QD
Arm Type: Placebo Comparator

Intervention Name: Placebo
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
            </arms>
            <measurements>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.72" sampleSize="241" stdDev="8.057046667358954"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.63" sampleSize="244" stdDev="8.060177665535667"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.88" sampleSize="243" stdDev="8.059232407617987"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.86" sampleSize="250" stdDev="8.063808033429368"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.47" sampleSize="120" stdDev="8.062476046476045"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.47" sampleSize="241" stdDev="7.110072010887091"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.38" sampleSize="244" stdDev="7.107327205075055"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.61" sampleSize="243" stdDev="7.108336514262673"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.74" sampleSize="250" stdDev="7.099313347078011"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.69" sampleSize="120" stdDev="7.109438796417057"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.71" sampleSize="241" stdDev="7.606845601167412"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.43" sampleSize="244" stdDev="7.60718318433308"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.87" sampleSize="243" stdDev="7.607167146842509"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="250" stdDev="7.605277772704952"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.59" sampleSize="120" stdDev="7.613343549321809"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-6.82" sampleSize="274" stdDev="8.855825766127065"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-6.86" sampleSize="276" stdDev="8.854861037870668"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.42" sampleSize="279" stdDev="8.852745336899735"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-6.91" sampleSize="280" stdDev="8.85186308073052"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.21" sampleSize="140" stdDev="8.862287515083224"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-6.98" sampleSize="241" stdDev="8.274385113106593"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.9" sampleSize="244" stdDev="8.278864656461053"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-7.79" sampleSize="243" stdDev="8.277470809371666"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.62" sampleSize="250" stdDev="8.269356081340312"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.96" sampleSize="120" stdDev="8.270610618328009"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="185" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="196" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="205" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="208" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="67" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.96" sampleSize="241" stdDev="9.531843263503655"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.93" sampleSize="244" stdDev="9.528504604606118"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.68" sampleSize="242" stdDev="9.520485701895675"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.56" sampleSize="250" stdDev="9.534267145407663"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.12" sampleSize="120" stdDev="9.530372500589891"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.72" sampleSize="241" stdDev="12.34171888352672"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-14.05" sampleSize="244" stdDev="12.340194487932514"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-15.18" sampleSize="243" stdDev="12.330469699082839"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-13.07" sampleSize="250" stdDev="12.33288287465668"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.36" sampleSize="120" stdDev="12.33471199501634"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.15" sampleSize="241" stdDev="11.006639859648356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.48" sampleSize="244" stdDev="10.996831543676569"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.62" sampleSize="243" stdDev="11.005450831292647"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.56" sampleSize="250" stdDev="11.00472625738596"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.4" sampleSize="120" stdDev="10.998268954703736"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="117" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="125" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="145" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="133" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="20" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.57" sampleSize="241" stdDev="11.658655196891278"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.75" sampleSize="244" stdDev="11.652892516452727"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.96" sampleSize="243" stdDev="11.644577579285562"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.73" sampleSize="250" stdDev="11.652993177720477"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.54" sampleSize="120" stdDev="11.655536023709935"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-14.28" sampleSize="274" stdDev="15.824615761527987"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-14.47" sampleSize="276" stdDev="15.815811834996014"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-17.58" sampleSize="279" stdDev="15.818018554800092"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-14.87" sampleSize="280" stdDev="15.812874501494028"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-2.06" sampleSize="140" stdDev="15.819597340008373"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-11.1" sampleSize="241" stdDev="12.12438043777908"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.39" sampleSize="244" stdDev="12.105886997655315"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.35" sampleSize="243" stdDev="12.11223129732916"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.13" sampleSize="250" stdDev="12.111523438444893"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.97" sampleSize="120" stdDev="12.104668520864172"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="131" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="139" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="158" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="149" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="24" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.15" sampleSize="241" stdDev="13.412886937568661"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.39" sampleSize="244" stdDev="13.402388443855818"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.42" sampleSize="242" stdDev="13.409572998421687"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.1" sampleSize="250" stdDev="13.408057279113928"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.21" sampleSize="120" stdDev="13.408248207726466"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="10" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="11" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="16" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="10" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="3" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="13" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="9" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="16" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="9" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="10" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="23" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="19" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="32" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="18" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="13" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="8" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="2" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="3" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="141"/>
                        <category name="45-64" rate="758"/>
                        <category name="&gt; 64" rate="376"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="32"/>
                        <category name="45-64" rate="173"/>
                        <category name="&gt; 64" rate="78"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="29"/>
                        <category name="45-64" rate="187"/>
                        <category name="&gt; 64" rate="67"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="37"/>
                        <category name="45-64" rate="161"/>
                        <category name="&gt; 64" rate="87"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="32"/>
                        <category name="45-64" rate="153"/>
                        <category name="&gt; 64" rate="97"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="11"/>
                        <category name="45-64" rate="84"/>
                        <category name="&gt; 64" rate="47"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="635"/>
                        <category name="Male" rate="640"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="150"/>
                        <category name="Male" rate="133"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="141"/>
                        <category name="Male" rate="142"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="136"/>
                        <category name="Male" rate="149"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="142"/>
                        <category name="Male" rate="140"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="66"/>
                        <category name="Male" rate="76"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
            </measurements>
            <epochs>
                <epoch name="Randomization">
                    <notes/>
                </epoch>
                <epoch name="Main phase">
                    <notes/>
                </epoch>
            </epochs>
            <activities>
                <studyActivity name="Randomization">
                    <activity>
                        <predefined>RANDOMIZATION</predefined>
                    </activity>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 20 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <usedBy epoch="Randomization" arm="Olmesartan 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 20">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="20.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 20 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 40">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 80">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="80.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Olmesartan">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Olmesartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Olmesartan 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Placebo">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="0.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Placebo"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
            </activities>
            <notes>
                <note source="CLINICALTRIALS">NCT00696241</note>
                <note source="MANUAL">This is one of the "main studies" supporting the Edarbi application for monotherapy identified in the EMA EPAR available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002293/WC500119206.pdf

Retrieved from ClinicalTrials.gov using the Takeda internal study identifier 491-008.</note>
            </notes>
        </study>
        <study name="NCT00696436">
            <indication name="Hypertensive disorder">
                <notes>
                    <note source="CLINICALTRIALS">Hypertension</note>
                </notes>
            </indication>
            <characteristics>
                <title>
                    <value>An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Brief title: An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Official title: A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension</note>
                    </notes>
                </title>
                <allocation>
                    <value>RANDOMIZED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </allocation>
                <blinding>
                    <value>DOUBLE_BLIND</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </blinding>
                <centers>
                    <value>131</value>
                    <notes>
                        <note source="CLINICALTRIALS">Alabaster, Alabama, United States
Ozark, Alabama, United States
Green Valley, Arizona, United States
Litchfield Park, Arizona, United States
Mesa, Arizona, United States
Tempe, Arizona, United States
Carmichael, California, United States
Chula Vista, California, United States
Lincoln, California, United States
Mission Viejo, California, United States
National City, California, United States
Pasadena, California, United States
Riverside, California, United States
Sacramento, California, United States
San Diego, California, United States
San Dimas, California, United States
San Fransisco, California, United States
San Ramon, California, United States
Santa Ana, California, United States
Vista, California, United States
Colorado Springs, Colorado, United States
Denver, Colorado, United States
Littleton, Colorado, United States
Longmont, Colorado, United States
Cape Coral, Florida, United States
Clearwater, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
New Port Richey, Florida, United States
New Smyrna Beach, Florida, United States
Palm Harbor, Florida, United States
Tallahassee, Florida, United States
Dunwoody, Georgia, United States
Roswell, Georgia, United States
Arlington Heights, Illinois, United States
Belleville, Illinois, United States
Champaign, Illinois, United States
Chicago, Illinois, United States
Peoria, Illinois, United States
Vernon Hills, Illinois, United States
Evansville, Indiana, United States
Indianapolis, Indiana, United States
Terre Haute, Indiana, United States
Kansas City, Kansas, United States
Overland Park, Kansas, United States
Shawnee, Kansas, United States
Biddeford, Maine, United States
Norwood, Maine, United States
Baltimore, Maryland, United States
Towson, Maryland, United States
Brooklyn Center, Minnesota, United States
Chesterfield, Missouri, United States
Jefferson City, Missouri, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Billings, Montana, United States
Las Vegas, Nevada, United States
Margate, New Jersey, United States
Glens Falls, New York, United States
Great Neck, New York, United States
New Hyde Park, New York, United States
New Windsor, New York, United States
New York, New York, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
Columbus, Ohio, United States
Norman, Oklahoma, United States
Tulsa, Oklahoma, United States
Yukon, Oklahoma, United States
Ashland, Oregon, United States
Eugene, Oregon, United States
Medford, Oregon, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Tipton, Pennsylvania, United States
Charleston, South Carolina, United States
Murrells Inlet, South Carolina, United States
North Charleston, South Carolina, United States
Cleveland, Tennessee, United States
Bedford, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Missouri City, Texas, United States
San Antonio, Texas, United States
Sugarland, Texas, United States
Tacoma, Washington, United States
Carlos Paz, Crdoba, Argentina
Guaymayen, Mendoza, Argentina
Baha Blanca, Argentina
Berazategui, Argentina
Buenos Aires, Argentina
Corrientes, Argentina
Crdoba, Argentina
Haedo Pcia. de Buenos Aires, Argentina
Jujuy, Argentina
La Plata, Argentina
Ramos Meja Pcia. de Buenos Aires, Argentina
Rosario, Argentina
Salta, Argentina
San Miguel de Tucumn, Argentina
Belo Horizonte, Brazil
Campinas, Brazil
Fortaleza, Brazil
Goiaenia, Brazil
Joildille, Brazil
Porto Alegre, Brazil
Rio Janeiro, Brazil
Sao Paulo, Brazil
Sorocava, Brazil
Tijuana, Baja California, Mexico
Len, Guanajuato, Mexico
Guadalajara, Jalapa, Mexico
Monterrey, Nuevo Leon, Mexico
Xalapa, Veracruz, Mexico
Aguascalientes, Mexico
Chihuahua, Mexico
Mexico City, Mexico
Quertaro, Mexico
San Luis Potos, Mexico
Arequipa, Peru
Cusco, Peru
Huaura, Peru
Ica, Peru
Lima, Peru
Trujillo, Peru
Aguas Buenas, Puerto Rico
Carolina, Puerto Rico
Jardines de Loiza, Puerto Rico
Orocovis, Puerto Rico
Ponce, Puerto Rico
San Juan, Puerto Rico
</note>
                    </notes>
                </centers>
                <objective>
                    <value>The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil,once daily (QD), compared to placebo, valsartan and olmesartan in participants withessential hypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil,once daily (QD), compared to placebo, valsartan and olmesartan in participants withessential hypertension.</note>
                    </notes>
                </objective>
                <study_start>
                    <value>2008-04-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">April 2008</note>
                    </notes>
                </study_start>
                <study_end>
                    <value>2009-08-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">August 2009</note>
                    </notes>
                </study_end>
                <status>
                    <value>COMPLETED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Completed</note>
                    </notes>
                </status>
                <inclusion>
                    <value>1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mmHg, inclusive, at Day 1).

2. Capable of understanding and complying with protocol requirements.

3. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study

4. Clinical laboratory evaluations within the reference range for the testing laboratoryor the results are deemed not clinically significant for inclusion into this study bythe investigator.

5. Willing to discontinue current antihypertensive medications at Screening Day 21visit. If the participant is on amlodipine prior to Screening, the participant iswilling to discontinue this medication at Screening Day -28.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mmHg, inclusive, at Day 1).

2. Capable of understanding and complying with protocol requirements.

3. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study

4. Clinical laboratory evaluations within the reference range for the testing laboratoryor the results are deemed not clinically significant for inclusion into this study bythe investigator.

5. Willing to discontinue current antihypertensive medications at Screening Day 21visit. If the participant is on amlodipine prior to Screening, the participant iswilling to discontinue this medication at Screening Day -28.

Exclusion Criteria:

1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior toRandomization).

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. Taking or expected to take an excluded medication as described in the ExcludedMedications.

4. Hypersensitive to angiotensin II receptor blockers.

5. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

6. Clinically significant cardiac conduction defects.

7. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

8. Secondary hypertension of any etiology.

9. Noncompliant (less than 70% or greater than 130%) with study medication during run-inperiod.

10. Moderate to severe renal dysfunction or disease.

11. Known or suspected unilateral or bilateral renal artery stenosis.

12. History of drug or alcohol abuse within the past 2 years.

13. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug. (This criterion does not apply to those participantswith basal cell or stage I squamous cell carcinoma of the skin).

14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greaterthan 8.0%) at Screening.

15. Hyperkalemia as defined by the central laboratory normal reference range atScreening.

16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

17. Upper arm circumference less than 24 cm or greater than 42 cm.

18. Works night (3rd) shift (defined as 11 PM [2300] to 7 AM [0700]).

19. Unwilling or unable to comply with the protocol or scheduled appointments.

20. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to Randomization.

21. Any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the subject according to the protocol.

22. Has been randomized in a previous azilsartan medoxomil study.

23. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</note>
                    </notes>
                </inclusion>
                <exclusion>
                    <value>1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior toRandomization).

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. Taking or expected to take an excluded medication as described in the ExcludedMedications.

4. Hypersensitive to angiotensin II receptor blockers.

5. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

6. Clinically significant cardiac conduction defects.

7. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

8. Secondary hypertension of any etiology.

9. Noncompliant (less than 70% or greater than 130%) with study medication during run-inperiod.

10. Moderate to severe renal dysfunction or disease.

11. Known or suspected unilateral or bilateral renal artery stenosis.

12. History of drug or alcohol abuse within the past 2 years.

13. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug. (This criterion does not apply to those participantswith basal cell or stage I squamous cell carcinoma of the skin).

14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greaterthan 8.0%) at Screening.

15. Hyperkalemia as defined by the central laboratory normal reference range atScreening.

16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

17. Upper arm circumference less than 24 cm or greater than 42 cm.

18. Works night (3rd) shift (defined as 11 PM [2300] to 7 AM [0700]).

19. Unwilling or unable to comply with the protocol or scheduled appointments.

20. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to Randomization.

21. Any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the subject according to the protocol.

22. Has been randomized in a previous azilsartan medoxomil study.

23. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mmHg, inclusive, at Day 1).

2. Capable of understanding and complying with protocol requirements.

3. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study

4. Clinical laboratory evaluations within the reference range for the testing laboratoryor the results are deemed not clinically significant for inclusion into this study bythe investigator.

5. Willing to discontinue current antihypertensive medications at Screening Day 21visit. If the participant is on amlodipine prior to Screening, the participant iswilling to discontinue this medication at Screening Day -28.

Exclusion Criteria:

1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior toRandomization).

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. Taking or expected to take an excluded medication as described in the ExcludedMedications.

4. Hypersensitive to angiotensin II receptor blockers.

5. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

6. Clinically significant cardiac conduction defects.

7. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

8. Secondary hypertension of any etiology.

9. Noncompliant (less than 70% or greater than 130%) with study medication during run-inperiod.

10. Moderate to severe renal dysfunction or disease.

11. Known or suspected unilateral or bilateral renal artery stenosis.

12. History of drug or alcohol abuse within the past 2 years.

13. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug. (This criterion does not apply to those participantswith basal cell or stage I squamous cell carcinoma of the skin).

14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greaterthan 8.0%) at Screening.

15. Hyperkalemia as defined by the central laboratory normal reference range atScreening.

16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

17. Upper arm circumference less than 24 cm or greater than 42 cm.

18. Works night (3rd) shift (defined as 11 PM [2300] to 7 AM [0700]).

19. Unwilling or unable to comply with the protocol or scheduled appointments.

20. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to Randomization.

21. Any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the subject according to the protocol.

22. Has been randomized in a previous azilsartan medoxomil study.

23. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</note>
                    </notes>
                </exclusion>
                <references>
                    <pubMedId>21282560</pubMedId>
                </references>
                <source>
                    <value>CLINICALTRIALS</value>
                    <notes>
                        <note source="CLINICALTRIALS">http://clinicaltrials.gov/show/NCT00696436</note>
                    </notes>
                </source>
                <creation_date>
                    <value>2012-09-24</value>
                    <notes>
                        <note source="CLINICALTRIALS">Information obtained from ClinicalTrials.gov on September 20, 2012</note>
                    </notes>
                </creation_date>
            </characteristics>
            <studyOutcomeMeasures>
                <studyOutcomeMeasure id="endpoint-SBP 24-hour mean" primary="true">
                    <endpoint name="SBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="SBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 24-hour mean" primary="false">
                    <endpoint name="DBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="DBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP daytime mean" primary="false">
                    <endpoint name="SBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP daytime mean" primary="false">
                    <endpoint name="DBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP nighttime mean" primary="false">
                    <endpoint name="SBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP nighttime mean" primary="false">
                    <endpoint name="DBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 12-hour mean" primary="false">
                    <endpoint name="SBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 12-hour mean" primary="false">
                    <endpoint name="DBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP trough mean" primary="false">
                    <endpoint name="SBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP trough mean" primary="false">
                    <endpoint name="DBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP response (clinic)" primary="false">
                    <endpoint name="SBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline  20 mm Hg
Description: Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP response (clinic)" primary="false">
                    <endpoint name="DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline  10 mm Hg
Description: Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)" primary="false">
                    <endpoint name="SBP and DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
Description: Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-SAE" primary="false">
                    <adverseEvent name="SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, serious adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Eye irritation" primary="false">
                    <adverseEvent name="Eye irritation"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Eye irritation (Eye disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions" primary="false">
                    <adverseEvent name="Abdominal adhesions"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Abdominal adhesions (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage" primary="false">
                    <adverseEvent name="Gastrointestinal haemorrhage"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gastrointestinal haemorrhage (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cholecystitis" primary="false">
                    <adverseEvent name="Cholecystitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cholecystitis (Hepatobiliary disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cholelithiasis" primary="false">
                    <adverseEvent name="Cholelithiasis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cholelithiasis (Hepatobiliary disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cellulitis" primary="false">
                    <adverseEvent name="Cellulitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cellulitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Diverticulitis" primary="false">
                    <adverseEvent name="Diverticulitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Diverticulitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Infected bites" primary="false">
                    <adverseEvent name="Infected bites"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Infected bites (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Fall" primary="false">
                    <adverseEvent name="Fall"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Fall (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Intentional overdose" primary="false">
                    <adverseEvent name="Intentional overdose"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Intentional overdose (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Subdural haematoma" primary="false">
                    <adverseEvent name="Subdural haematoma"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Subdural haematoma (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Blood pressure increased" primary="false">
                    <adverseEvent name="Blood pressure increased"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Blood pressure increased (Investigations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Breast cancer" primary="false">
                    <adverseEvent name="Breast cancer"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Breast cancer (Neoplasms benign, malignant and unspecified (incl cysts and polyps))</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Partial seizures" primary="false">
                    <adverseEvent name="Partial seizures"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Partial seizures (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding" primary="false">
                    <adverseEvent name="Dysfunctional uterine bleeding"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Dysfunctional uterine bleeding (Reproductive system and breast disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis" primary="false">
                    <adverseEvent name="Deep vein thrombosis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Deep vein thrombosis (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Non-SAE" primary="false">
                    <adverseEvent name="Non-SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, other adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Headache" primary="false">
                    <adverseEvent name="Headache"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Headache (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)" primary="false">
                    <populationCharacteristic name="Age (cut-off 45, 65)"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Gender" primary="false">
                    <populationCharacteristic name="Gender"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gender
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
            </studyOutcomeMeasures>
            <arms>
                <arm name="Azilsartan Medoxomil 40 mg QD" size="280">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 40 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 80 mg QD" size="285">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 80 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</note>
                    </notes>
                </arm>
                <arm name="Valsartan 320 mg QD" size="282">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Valsartan 320 mg QD
Arm Type: Active Comparator

Intervention Name: Valsartan
Intervention Type: Drug
Intervention Description: Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</note>
                    </notes>
                </arm>
                <arm name="Olmesartan 40 mg QD" size="290">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Olmesartan 40 mg QD
Arm Type: Active Comparator

Intervention Name: Olmesartan
Intervention Type: Drug
Intervention Description: Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</note>
                    </notes>
                </arm>
                <arm name="Placebo QD" size="154">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Placebo QD
Arm Type: Placebo Comparator

Intervention Name: Placebo
Intervention Type: Drug
Intervention Description: Matching placebo, orally, once daily for up to six weeks.</note>
                    </notes>
                </arm>
            </arms>
            <measurements>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-9.16" sampleSize="237" stdDev="8.343983940540634"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-10.13" sampleSize="229" stdDev="8.338143018682278"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="254" stdDev="8.351185784066836"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.01" sampleSize="134" stdDev="8.346178406911752"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-7.42" sampleSize="234" stdDev="8.36749102180576"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.65" sampleSize="237" stdDev="7.2663476382567875"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-9.43" sampleSize="229" stdDev="7.263718056202347"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.74" sampleSize="254" stdDev="7.267444117432208"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.07" sampleSize="134" stdDev="7.258049738049471"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-7.09" sampleSize="234" stdDev="7.2813998654104966"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.96" sampleSize="237" stdDev="7.851350202353733"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-9.8" sampleSize="229" stdDev="7.838762402318366"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="254" stdDev="7.84118970565054"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.01" sampleSize="134" stdDev="7.836841583188983"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-7.23" sampleSize="234" stdDev="7.862688089960074"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-6.97" sampleSize="269" stdDev="9.053473145704913"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.27" sampleSize="270" stdDev="9.053853875560396"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-6.1" sampleSize="283" stdDev="9.05056086659827"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.76" sampleSize="148" stdDev="9.05115064508375"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-5.11" sampleSize="271" stdDev="9.054142698234882"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.65" sampleSize="237" stdDev="8.313194331903953"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.54" sampleSize="229" stdDev="8.323010272731857"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="254" stdDev="8.319311029165817"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.1" sampleSize="134" stdDev="8.311450896203382"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-6.26" sampleSize="234" stdDev="8.321599846183426"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="185" sampleSize="269"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="192" sampleSize="270"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="193" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="65" sampleSize="148"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="173" sampleSize="271"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.69" sampleSize="236" stdDev="9.954764889237715"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.61" sampleSize="229" stdDev="9.942214089426963"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-8.25" sampleSize="254" stdDev="9.944923529117759"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.69" sampleSize="134" stdDev="9.943643899496804"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-6.22" sampleSize="234" stdDev="9.95838511004671"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-14.03" sampleSize="237" stdDev="11.76163049921226"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-15.55" sampleSize="229" stdDev="11.75814360347755"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.23" sampleSize="254" stdDev="11.76178455847581"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.1" sampleSize="134" stdDev="11.761050293234868"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-10.44" sampleSize="234" stdDev="11.778735076399334"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.42" sampleSize="237" stdDev="10.62241497965505"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.53" sampleSize="229" stdDev="10.623187657195931"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.99" sampleSize="254" stdDev="10.614293382039147"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.25" sampleSize="134" stdDev="10.615042439858637"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-10.22" sampleSize="234" stdDev="10.646752744381734"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="132" sampleSize="269"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="142" sampleSize="270"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="126" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="27" sampleSize="148"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="119" sampleSize="271"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.73" sampleSize="237" stdDev="11.145838326478632"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-15.02" sampleSize="229" stdDev="11.137701019510265"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.16" sampleSize="254" stdDev="11.14022683790595"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.11" sampleSize="134" stdDev="11.147530937386987"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-10.26" sampleSize="234" stdDev="11.166852734768199"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-16.38" sampleSize="269" stdDev="15.728769468715601"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-16.74" sampleSize="270" stdDev="15.725114625973317"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-13.2" sampleSize="283" stdDev="15.729134591578775"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.83" sampleSize="148" stdDev="15.730023903351194"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-11.31" sampleSize="271" stdDev="15.721284139662384"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.28" sampleSize="237" stdDev="11.977157759669028"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.32" sampleSize="229" stdDev="11.985134792733874"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.9" sampleSize="254" stdDev="11.98490784278294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.31" sampleSize="134" stdDev="11.980991194387883"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-9.66" sampleSize="234" stdDev="11.992893895970232"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="152" sampleSize="269"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="156" sampleSize="270"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="138" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="33" sampleSize="148"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="132" sampleSize="271"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.46" sampleSize="236" stdDev="13.211570686334005"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.38" sampleSize="229" stdDev="13.210887214718019"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.65" sampleSize="254" stdDev="13.212085906472149"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.55" sampleSize="134" stdDev="13.219605742986436"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-9.14" sampleSize="234" stdDev="13.231955637773277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="18" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="12" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="23" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="14" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="21" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="18" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="12" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="23" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="14" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="21" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="2" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="3" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="4" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="2" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="3" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="194"/>
                        <category name="45-64" rate="815"/>
                        <category name="&gt; 64" rate="282"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="41"/>
                        <category name="45-64" rate="170"/>
                        <category name="&gt; 64" rate="69"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="38"/>
                        <category name="45-64" rate="184"/>
                        <category name="&gt; 64" rate="63"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="39"/>
                        <category name="45-64" rate="185"/>
                        <category name="&gt; 64" rate="66"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="20"/>
                        <category name="45-64" rate="98"/>
                        <category name="&gt; 64" rate="36"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="56"/>
                        <category name="45-64" rate="178"/>
                        <category name="&gt; 64" rate="48"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="592"/>
                        <category name="Male" rate="699"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="133"/>
                        <category name="Male" rate="147"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="134"/>
                        <category name="Male" rate="151"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="131"/>
                        <category name="Male" rate="159"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="64"/>
                        <category name="Male" rate="90"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="130"/>
                        <category name="Male" rate="152"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
            </measurements>
            <epochs>
                <epoch name="Randomization">
                    <notes/>
                </epoch>
                <epoch name="Main phase">
                    <notes/>
                </epoch>
            </epochs>
            <activities>
                <studyActivity name="Randomization">
                    <activity>
                        <predefined>RANDOMIZATION</predefined>
                    </activity>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <usedBy epoch="Randomization" arm="Olmesartan 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Placebo QD"/>
                    <usedBy epoch="Randomization" arm="Valsartan 320 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 20-40">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="20.0" maxDose="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 40-80">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="40.0" maxDose="80.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Valsartan">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="160.0" maxDose="320.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Valsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Valsartan 320 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Olmesartan">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="20.0" maxDose="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Olmesartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Olmesartan 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Placebo">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="0.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Placebo"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
            </activities>
            <notes>
                <note source="CLINICALTRIALS">NCT00696436</note>
                <note source="MANUAL">This is one of the "main studies" supporting the Edarbi application for monotherapy identified in the EMA EPAR available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002293/WC500119206.pdf

Retrieved from ClinicalTrials.gov using the Takeda internal study identifier 491-019.</note>
            </notes>
        </study>
    </studies>
    <metaAnalyses/>
    <benefitRiskAnalyses/>
</addis-data>
